Catalyst

Slingshot members are tracking this event:

Trillium Therapeutics'(TRIL) TTI-622 in Refractory lymphoma or multiple myeloma Phase 1 update due at R&D Day April 28, 2021

Source Link:
https://ir.trilliumtherapeutics.com/press-releases/press-release-details/2021/Trillium-Therapeutics-Reports-Annual-Operating-and-Financial-Results-and-Sets-Date-for-RD-Day/default.aspx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TRIL Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Apr 18, 2021
Occurred Source:
https://ir.trilliumtherapeutics.com/press-releases/press-release-details/2021/Trillium-Therapeutics-Provides-Data-Update-Announces-Phase-1b2-Program-Priorities-Across-Hematologic-Malignancies-and-Solid-Tumors-and-Reports-Governance-Changes/default.aspx
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Tti-622, Refractory Lymphoma, Multiple Myeloma
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.